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Reply to M. Horiguchi et al
We thank Horiguchi et al1 for their thoughtful correspon-
dence regarding our article2 and their observation that the proﬁle
of the Kaplan-Meier curves is suggestive of nonproportional hazards.
This is indeed the case, but the statistical evidence for this is not
conclusive. In our prespeciﬁed statistical analysis plan for the study,
we did test the assumption of proportional hazards by ﬁtting
a time-varying covariable. We omitted this detail from the methods
described in the article; however, this test for lack of proportional
hazards was not statistically signiﬁcant (two-sided P 5 .13) and,
therefore, was not sufﬁcient to indicate that we should not proceed
with our plan to analyze the results under the proportional hazards
assumption.
The authors are correct to state that deviation of the study data
from the assumption of proportional hazards will affect the sta-
tistical power to detect treatment differences, and we did conduct
a sensitivity analysis using a restricted mean survival time (RMST)
approach.3 After adjusting for stratiﬁcation factors, the RMSTwas
1.5 months lower in the pazopanib arm compared with paclitaxel
arm (80%CI,22.7 to20.3 months; unadjusted one-sided P5.96,
on the basis of a truncation time of 17.9 months). This is stronger
evidence for the superiority of paclitaxel than using the pro-
portional hazards approach, which had a P value of .89. We note
in passing that we used 80% CIs to be consistent with the stated
signiﬁcance level for the study (10% one-sided).
We disagree with the statement that “it is puzzling that for
almost all cancer studies…there were no formal comparisons
performed between two median OS [overall survival] times.” The
median overall survival is a useful summary statistic for the in-
dividual Kaplan-Meier curves, but for the vast majority of studies,
the primary analysis is based on the comparison of event rates over
the whole follow-up period, with the corresponding summary
statistic being the hazard ratio. The suitability of this approach
depends, as previously noted, on the assumption of proportional
hazards, but if this assumption is not fulﬁlled, we would rather fall
back on the RMSTapproach rather than a comparison of medians,
because this makes greater use of all the data available. In this
particular situation, the comparison of the medians corresponds to
the point where the difference between the curves is greatest and
could be criticized as data prompted and therefore biased.
We do agree that it can be difﬁcult to represent the difference
between survival curves in a single summary measure when
proportional hazards do not apply. In these situations, we do think
that RMST is a useful alternative (although not ideal because it
depends on follow-up time) and provides a better approach than,
say, a landmark analysis or a comparison of medians because it
makes greater use of the information available. However, we ﬁnally
note that none of the points mentioned affect the fundamental
ﬁnding of the study that, regrettably, pazopanib conclusively had
no greater efﬁcacy than paclitaxel in this setting.
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